Uptake of Infliximab Biosimilars Among the Medicare Population
Alice J Chen1,2, Laura Gascue1, Rocio Ribero1
1Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles.
No abstract available in PubMed .
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Bioavailability: Overview
